SHIELD THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.4 GBX | +17.07% |
|
+29.73% | -64.18% |
| May. 10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
| Sales 2024 * | 24.13M 30.63M | Sales 2025 * | 71.12M 90.26M | Capitalization | 18.77M 23.82M |
|---|---|---|---|---|---|
| Net income 2024 * | -18M -22.85M | Net income 2025 * | 3M 3.81M | EV / Sales 2024 * | 1.72 x |
| Net Debt 2024 * | 22.86M 29.01M | Net Debt 2025 * | 20.43M 25.93M | EV / Sales 2025 * | 0.55 x |
| P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
4.7
x | Employees | 27 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Shield Therapeutics plc
More recommendations
More press releases
| 1 day | +17.07% | ||
| 1 week | +29.73% | ||
| Current month | +77.78% | ||
| 1 month | +68.42% | ||
| 3 months | -15.79% | ||
| 6 months | -60.00% | ||
| Current year | -64.18% |
1 week
1.68
2.45
1 month
1.062.45
Current year
1.067.80
1 year
1.0612.85
3 years
1.0662.60
5 years
1.06202.00
10 years
1.06202.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 18-07-25 | |
| Director/Board Member | 66 | 16-01-31 | |
| Director/Board Member | 57 | 21-05-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 2.4 | +17.07% | 22 022 594 |
| 24-05-22 | 2.05 | +6.49% | 8,874,966 |
| 24-05-21 | 1.925 | +10.00% | 2,828,745 |
| 24-05-20 | 1.75 | 0.00% | 633,780 |
| 24-05-17 | 1.75 | -5.41% | 3,816,322 |
Delayed Quote London S.E., May 23, 2024 at 11:40 am EDT
More quotes
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Calendar
2024-06-20
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0205
GBP
Average target price
0.16
GBP
Spread / Average Target
+680.49%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -64.18% | 20.4M | |
| +10.66% | 115B | |
| +11.58% | 106B | |
| -6.38% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.13% | 17.56B | |
| -40.50% | 17.32B | |
| +6.38% | 14.03B | |
| +31.88% | 12.13B |
- Stock Market
- Equities
- STX Stock
